Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Boston Scientific (BSX)
NYSE:BSX
Earnings Data
Report Date
Apr 23, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.67Last Year’s EPS
0.56Same Quarter Last Year
Strong Buy
Based on 23 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 05, 2025
|% Change Since: 1.76%
|Next Earnings Date:Apr 23, 2025
Earnings Call Sentiment|Positive
The earnings call reflects strong operational and financial performance with significant growth in key areas such as electrophysiology and Watchmen sales. Despite challenges in China and currency impacts, the company exceeded its financial guidance and demonstrated solid strategic execution.Company Guidance
During the call, Boston Scientific provided guidance for 2025, projecting organic revenue growth between 10% and 12% for the full year. They anticipate adjusted earnings per share (EPS) to be in the range of $2.80 to $2.87, reflecting growth of 12% to 14%. Operational revenue growth is expected to be between 13.5% and 15.5%, excluding a 350 basis point contribution from closed acquisitions. The company also expects first-quarter organic revenue growth to be between 14% and 16%. Additionally, Boston Scientific aims for an adjusted operating margin expansion of 50 to 75 basis points, improving from the full-year 2024 adjusted gross margin of 70.3%. They forecast a free cash flow in excess of $3 billion for 2025, emphasizing strategic tuck-in mergers and acquisitions as a key capital allocation priority.Record Growth in Operational and Organic Sales
Operational sales grew 23% in Q4 and 18.5% for the full year 2024. Organic sales grew 20% in Q4 and 16% for the full year, both exceeding guidance.
Strong Adjusted EPS Growth
Q4 adjusted EPS grew 26% to $0.70, exceeding guidance. Full-year adjusted EPS grew 22% to $2.51, surpassing expectations.
Electrophysiology and FerraPulse Success
Electrophysiology sales grew 172% in Q4 and 139% for the full year. FerraPulse surpassed $1 billion in revenue globally.
Watchmen Sales Growth
Watchmen sales grew 20% in Q4 and 19% for the full year, supported by new DRG and positive trial data.
Strong Free Cash Flow Performance
Free cash flow for the full year 2024 was $2.648 billion, achieving 71% free cash flow conversion.
---
BSX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BSX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 05, 2025 | $103.54 | $104.97 | +1.38% |
| Oct 23, 2024 | $88.01 | $87.45 | -0.64% |
| Jul 24, 2024 | $78.59 | $77.76 | -1.06% |
| Apr 24, 2024 | $68.99 | $72.91 | +5.68% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Boston Scientific (BSX) report earnings?
Boston Scientific (BSX) is schdueled to report earning on Apr 23, 2025, TBA Not Confirmed.
What is Boston Scientific (BSX) earnings time?
Boston Scientific (BSX) earnings time is at Apr 23, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BSX EPS forecast?
BSX EPS forecast for the fiscal quarter 2025 (Q1) is 0.67.
---
